New immune cell shot targets Hard-to-Treat blood cancers
NCT ID NCT07312630
First seen Jan 06, 2026 · Last updated May 19, 2026 · Updated 24 times
Summary
This early-phase study tests a new treatment called LV009 injection for people with certain blood cancers (non-Hodgkin lymphoma and acute lymphoblastic leukemia) that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to find and attack cancer cells that carry a protein called CD19. The main goal is to check safety and how the treatment behaves in the body, with 19 adults expected to take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
PersonGen.Anke Cellular Therapeutice Co., Ltd.
RECRUITINGHefei, Anhui, 230088, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.